(19)
(11)EP 4 222 267 A1

(12)

(43)Date of publication:
09.08.2023 Bulletin 2023/32

(21)Application number: 21810160.8

(22)Date of filing:  30.09.2021
(51)International Patent Classification (IPC): 
C12N 15/82(2006.01)
A61K 48/00(2006.01)
C12N 15/85(2006.01)
A61K 38/17(2006.01)
C12N 15/63(2006.01)
(52)Cooperative Patent Classification (CPC):
A61K 48/0058; C12N 15/635; C12N 15/86; C12N 2740/16043; C12N 2830/50; C12N 2830/008; C12N 2830/48; C12N 2830/003; C12N 2830/001
(86)International application number:
PCT/US2021/052990
(87)International publication number:
WO 2022/072712 (07.04.2022 Gazette  2022/14)
(84)Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
Designated Extension States:
BA ME
Designated Validation States:
KH MA MD TN

(30)Priority: 30.09.2020 US 202063085983 P

(71)Applicant: Vor Biopharma Inc.
Cambridge, MA 02140 (US)

(72)Inventors:
  • KASSIM, Sadik
    Cambridge, MA 02140 (US)
  • CHAKRABORTY, Tirtha
    Cambridge, MA 02140 (US)
  • SCHERER, Julian
    Cambridge, MA 02140 (US)

(74)Representative: Hoffmann Eitle 
Patent- und Rechtsanwälte PartmbB Arabellastraße 30
81925 München
81925 München (DE)

  


(54)CHIMERIC ANTIGEN RECEPTOR EXPRESSION SYSTEMS